Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

August 21, 2017August 21, 2017

High-dose Vitamin C May Be Effective Against Lymphoma, Other Blood Cancers, Say Researchers

News

Vitamin C boosts processes that allow faulty blood stem cells to die instead of multiplying uncontrollably to cause lymphoma or other blood cancers, say researchers at NYU Langone Health‘s Perlmutter Cancer ... Read more

August 18, 2017

Adcetris Might Be Approved for CTCL by December, as FDA Reviews Marketing Application

News

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) required to bring Seattle Genetics’ Adcetris (brentuximab vedotin) to the market for the treatment ... Read more

August 14, 2017August 14, 2017

CAR T-Cell Therapy Shown to Eliminate Tumors in Some Chronic Lymphocytic Leukemia Patients During Trial

News

CAR T-cell immunotherapy was seen to eradicate or shrink tumors in 70% of patients with chronic lymphocytic leukemia (CLL) who had exhausted other treatment options, according to a clinical trial ... Read more

July 20, 2017

Sutro Says STRO-001 Wiped Out or Slowed Growth of Lymphoma and Myeloma in Animals

News

Sutro Biopharma says its therapy STRO-001 either eradicated or significantly slowed the growth of non-Hodgkin lymphoma and multiple myeloma in animal models. The preclinical-trial findings supported Sutro’s submission of an investigational ... Read more

July 18, 2017July 18, 2017

Revlimid-Rituxan Combo Proves Effective Against Hard-to-Treat Non-Hodgkin’s Lymphomas, Trial Shows

News

Seventy percent of follicular lymphoma patients treated with a combination of Revlimid and Rituxan went a year without their cancer progressing, according to interim Phase 3 clinical trial results. Celgene, which developed Relimid, ... Read more

July 14, 2017

Advisory Committee Recommends That FDA Approve CTL019 for Treating Children with Leukemia

News

A U.S. Food and Drug Administration advisory committee has recommended that the agency approve Novartis’ CAR T-cell therapy CTL019 (tisagenlecleucel) as a treatment for children and young adults with leukemia. The Oncologic ... Read more

July 10, 2017July 10, 2017

Potential Oral Therapy for Indolent Non-Hodgkin’s Lymphoma, Duvelisib, Shows Efficacy in Phase 2 Trial

News

An investigative oral therapy, duvelisib, was effective in treating indolent non-Hodgkin’s lymphoma among patients who did not respond to Rituxan (rituximab) and chemotherapy or radioimmunotherapy, according to results from a Phase ... Read more

July 7, 2017July 7, 2017

Response to Kite’s CAR T-Cell Therapy in NHL Isn’t Dependent on Disease Factors, Researchers Say

News

The ZUMA-1 Phase 2 clinical trial of the CAR T-cell therapy axicabtagene ciloleucel (KTE-C19) showed that 82% of patients with treatment-resistant or relapsed aggressive non-Hodgkin’s lymphoma (NHL) responded to the ... Read more

June 30, 2017June 30, 2017

85% of Hodgkin Lymphoma Patients Respond to Adcetris-Opdivo Combo, Trial Shows

News

A combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) led to Hodgkin lymphoma diminishing in 85 percent of patients in a Phase 1/2 trial (NCT02572167), researchers reported. Among them, 63 ... Read more

June 16, 2017

FDA to Begin Reviewing Vyxeos as Treatment for Acute Myeloid Leukemia

News

The U.S. Food and Drug Administration has accepted Jazz Pharmaceuticals’ New Drug Application (NDA) for Vyxeos, an injected formulation of cytarabine and daunorubicin as a treatment for acute myeloid leukemia, ... Read more